SpecificationsOrganism/cell line/tissueMicroglial cells from brains of 8- to 9-month-old Cd11b-Cre EP2^+/+^ and Cd11b-Cre EP2^fl/fl^ mice in C57BL/6 backgroundSexFemale and male, see Table [1](#t0005){ref-type="table"}Sequencer or array typeAffymetrix GeneChip Mouse Gene 2.0 STData formatRawExperimental factorsMice received intracerebroventricular injection of Aβ~42~ fibrils or saline; 48 h later, the mice were sacrificed for brain dissection.Experimental featuresPrimary microglia were isolated from whole brains using magnetic cell sorting and processed immediately to isolate RNA.ConsentN/ASample source locationStanford, CA

1. Direct link to deposited data {#s0005}
================================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57181>.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Experimental design {#s0015}
------------------------

In the context of Aβ~42~ peptides in AD, microglia generate a potent inflammatory response. Microglia are also intimately associated with neurons and synapses and perform essential nonimmune functions important to normal neural function. Microglial EP2 signaling broadly regulates inflammatory and anti-inflammatory pathways in vivo. Previous findings suggested a harmful function of microglial EP2 signaling both in vitro and in vivo in models of Aβ~42~ inflammation, with potentiation of proinflammatory responses, suppression of immune cell trafficking and Aβ peptide clearance [@bb0010], [@bb0020]. We aimed to identify additional functions of microglial EP2 signaling and therefore examined microglial-specific gene expression in response to intracerebroventricular (i.c.v.) injection of Aβ~42~ peptides. Aβ~42~ peptide injection i.c.v. not only generates a robust, long-lasting innate immune response, but also disrupts memory consolidation, and thus represents a model in which to test effects of microglial EP2 on transcriptional responses. In a previous study [@bb0015], we analyzed the inflammatory response up to 7 days post i.c.v. injection. Forty-eight hours was chosen for this microarray study to avoid the immediate inflammatory response to the injection procedure while still capturing early changes in gene expression that may have subsided at later time points.

To examine cell-specific mechanisms of EP2-mediated innate immune responses in vivo, we generated an EP2^fl/−^ C57BL/6 J mouse line to allow for conditional deletion of EP2. The Cd11b-Cre line, which drives expression of Cre recombinase in the monocyte lineage (macrophages and microglia), was used to generate Cd11b-Cre EP2^fl/fl^ and control Cd11b-Cre EP2^+/+^ C57BL/6 mice. To analyze the response to Aβ~42~ peptides in adult brain, we used 8--9 month-old mice, as isolation of primary microglia becomes progressively more difficult at older ages.

2.2. Sample preparation and quality control {#s0020}
-------------------------------------------

Cd11b-Cre EP2^+/+^ control and Cd11b-Cre EP2^fl/fl^ mice were administered i.c.v. injection of Aβ~42~ fibrils (40 pmol) or saline vehicle as described previously [@bb0015]. At 48 h after surgery, mice were sacrificed by transcardiac perfusion with saline to ensure removal of blood cells from the brain. Brains were removed from the mice and pooled, 2 brains of the same genotype, sex, and treatment per sample. We found that pooling samples were required to ensure adequate cell and RNA yield. The brains were then enzymatically dissociated and microglia isolated using magnetic CD11b microbeads (Miltenyi Biotec) according to the manufacturer\'s protocol.

RNA purification from primary microglia was performed using TRIzol (Life Technologies) followed by the RNeasy Mini Kit (Qiagen). RNA quality was assessed using a BioAnalyzer (Agilent) and determined to be sufficient for microarray analysis (RNA Integrity Number \> 7.0 for all samples). cDNA synthesis, labeling, hybridization, and scanning were performed by the Stanford Protein and Nucleic Acid (PAN) Facility using GeneChip Mouse Gene 2.0 ST arrays (Affymetrix). Samples are described in [Table 1](#t0005){ref-type="table"}.

2.3. Microarray and data analysis {#s0025}
---------------------------------

Raw microarray data were statistically analyzed using Partek software (Partek, Inc.), using default RMA normalization and log2 transformation of data. These raw data were deposited in GEO (accession no. [GSE57181](ncbi-geo:GSE57181){#ir0020}). We used Partek to perform 2-way ANOVA analysis on the factors of Aβ treatment and genotype, with contrasts identifying the fold-change and significance of the Aβ-EP2 vs. Aβ-WT; Aβ-WT vs. Veh-WT; and Veh-EP2 vs. Veh-WT comparisons. We next identified differentially expressed genes in each contrast using an unadjusted P value of \< 0.05 to capture the widest possible number of differentially expressed genes. Genes that had a fold change of \> 1.5 between genotypes were used for unsupervised hierarchical clustering analysis and Gene Ontology (GO) expression analysis.

The first study [@bb0025] looked at changes in the innate inflammatory response to lipopolysaccharide (LPS) and the MPTP model of Parkinson\'s disease. Here we described the generation and initial analysis of the mice with Cd11b promotor-driven immune cell deletion of EP2 and the Cd11b-Cre EP2^fl/fl^ versus Cd11b-Cre EP2^+/+^ saline gene expression comparison. Quantification of EP2 mRNA in adult microglia used for microarray analysis revealed a decrease of 48% in Cd11b-Cre Ep2^fl/fl^ microglia. A total of 136 genes were identified that were differentially regulated and used to create the node map. Ingenuity Pathway Analysis (IPA, Ingenuity Systems) was used for pathway analysis. Unsupervised hierarchical clustering revealed a striking downregulation of a majority of microglial genes with EP2 deletion, with 116 genes significantly downregulated 1.5-fold and 20 genes upregulated by 1.5-fold. The principal biological functions represented by the differentially regulated genes included the immune response, cytoskeletal function, and cell cycle/mitosis. Immune molecules functioning in cytokine and chemokine signaling, chemotaxis and cell adhesion, and immune cell activation were significantly downregulated. Interestingly, cell cycle and mitosis as well as signaling molecules involved in cell cycle progression, cytoskeletal function, and chromatin assembly were also significantly downregulated. Together, the suppression of gene expression in these biological pathways suggests a decreased inflammatory and proliferative state of EP2 conditional knock-out microglia. To further define connections between immune molecules that were regulated by microglial EP2 signaling, we performed Ingenuity Pathway Analysis to define networks of differentially regulated immune genes (1.5-fold and greater) that were connected to each other either through regulation of expression or protein-protein binding. Interestingly, COX-2 was highly downregulated with EP2 deletion, and as COX-2 catalyzes the formation of PGH~2~, the precursor of PGE~2~ that activates the EP2 receptor, this suggests a feedforward cycle in which EP2-mediated increases in COX-2 expression results in further production of PGE~2~. Thus, conditional knock-out of microglial EP2 resulted in the downregulation of most inflammatory genes represented in the pathway, in large part through downregulation of COX-2, which drives expression of multiple immune genes.

In the second study [@bb0030], the comparison between Aβ- versus vehicle-injected Cd11b-Cre mice showed the Immune System Process as the most highly enriched (enrichment score, 94.42). There was a 1.3 fold induction of microglial EP2 in the Cd11b-Cre control genotype. Unsupervised hierarchical clustering of differentially expressed genes revealed a striking distinction between the i.c.v. Aβ and i.c.v. vehicle treatment groups. IPA of upstream regulatory transcription factors demonstrated 2 major nodes of inflammatory gene regulation, Nfkb and Irf7. In this comparison, COX-2 was highly induced in vivo in microglia from i.c.v. Aβ~42~-treated mice. Database for Annotation, Visualization and Integrated Discovery (DAVID) functional annotation software (version 6.7; NIAID, NIH) was used to identify KEGG molecular pathways significantly overrepresented among lists of the 416 transcripts differentially expressed in Aβ- versus vehicle-treated Cd11b-Cre mice. This analysis revealed 20 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that were significantly enriched, almost all of which corresponded to inflammatory signaling networks. Comparison of Aβ-treated Cd11b-Cre Ep2^fl/fl^ versus Cd11b-Cre mice revealed 55 regulated genes ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}), and hierarchical clustering of these genes across conditions demonstrated a clear segregation of Aβ-regulated genes in Cd11b-Cre Ep2^fl/fl^ mice. Comparison of KEGG pathways revealed shared pathways between the Aβ-treated Cd11b-Cre and vehicle-treated Cd11b-Cre groups and between the vehicle-treated Cd11b-Cre Ep2^fl/fl^ and vehicle-treated Cd11b-Cre groups. The complete set of enriched KEGG pathways in the Cd11b-Cre Ep2^fl/fl^ versus Cd11b-Cre comparison included cell cycle, proteolysis, and immune pathways [@bb0030]. Interestingly, the majority of differentially regulated genes in the Aβ-treated Cd11b-Cre Ep2^fl/fl^ versus Aβ-treated Cd11b-Cre comparison were not regulated by Aβ, but were specifically changed with microglial EP2 deletion (39 genes, [Table 3](#t0015){ref-type="table"}). This suggested that rather than simply reversing Aβ~42~-induced inflammatory changes, Cd11b-Cre Ep2^fl/fl^ microglia engaged alternative response pathways. Functional annotation of these genes using DAVID revealed an enrichment of PPAR signaling pathway genes. There were 16 genes regulated by \> 1.5-fold in both the Aβ-treated Cd11b-Cre versus vehicle-treated Cd11b-Cre comparison and the Aβ-treated Cd11b-Cre EP2^fl/fl^ versus Aβ-treated Cd11b-Cre comparison ([Table 2](#t0010){ref-type="table"}). Notably, all 16 of these genes are regulated in opposite directions by Aβ and EP2 deletion, suggesting that EP2 deletion reverses the transcriptional effects of Aβ on microglia cells. Included among these genes are the immune genes dual specificity phosphatase 1 and 2 and interleukin 1 receptor, type II.

3. Summary {#s0030}
==========

We analyzed in vivo Cd11b-Cre control and Cd11b-Cre EP2^fl/fl^ mouse brain microglia gene expression by microarray and following GO expression and pathway analyses. The results are described in two publications [@bb0025], [@bb0030],and here we provide a detailed description of the experiment and analysis, in addition to two new tables with gene changes. Of the three comparisons, vehicle- and Aβ-treated Cd11b-Cre showed the largest number of genes altered. Our results identify new candidates for further study in the inflammatory response of microglia in AD.

This work was supported by NIH grant RO1AG030209 (to K.I. Andreasson), NIH grant R21AG033914 (to K.I. Andreasson), Alzheimer\'s Association (IIRG-06-27502) (to K.I. Andreasson), Swedish Research Council (to J.U. Johansson), National Science Foundation (to N.S. Woodling), and NRSA grant F31AG039195 (to N.S. Woodling).

###### 

Samples used for microarray analysis.

  GEO ID ref   Sample ID   Genotype             Sex      Treatment   Cells (× 10\^6)   RIN score
  ------------ ----------- -------------------- -------- ----------- ----------------- -----------
  GSM1376787   Ab_EP2_1    Cd11b-Cre; EP2 f/f   Female   Aβ          2.40              9.8
  GSM1376788   Ab_EP2_2    Cd11b-Cre; EP2 f/f   Female   Aβ          2.40              9.9
  GSM1376789   Ab_EP2_3    Cd11b-Cre; EP2 f/f   Female   Aβ          2.00              8.7
  GSM1376790   Ab_WT_1     CD11b-Cre; +/+       Female   Aβ          2.30              9.7
  GSM1376791   Ab_WT_2     CD11b-Cre; +/+       Female   Aβ          1.65              9.4
  GSM1376792   Ab_WT_3     CD11b-Cre; +/+       Female   Aβ          2.30              7.0
  GSM1376793   Ab_WT_4     CD11b-Cre; +/+       Female   Aβ          1.75              7.7
  GSM1376794   Ab_WT_5     CD11b-Cre; +/+       Female   Aβ          1.65              8.5
  GSM1376795   Ab_WT_6     CD11b-Cre; +/+       Female   Aβ          0.95              9.6
  GSM1376796   Ab_WT_7     CD11b-Cre; +/+       Female   Aβ          2.75              9.0
  GSM1376797   Veh_EP2_1   Cd11b-Cre; EP2 f/f   Male     Veh         1.50              9.4
  GSM1376798   Veh_EP2_2   Cd11b-Cre; EP2 f/f   Female   Veh         1.90              9.1
  GSM1376799   Veh_EP2_3   Cd11b-Cre; EP2 f/f   Female   Veh         1.65              9.9
  GSM1376800   Veh_WT_1    CD11b-Cre; +/+       Male     Veh         1.12              9.8
  GSM1376801   Veh_WT_2    CD11b-Cre; +/+       Female   Veh         1.25              9.6
  GSM1376802   Veh_WT_3    CD11b-Cre; +/+       Female   Veh         1.50              8.6
  GSM1376803   Veh_WT_4    CD11b-Cre; +/+       Female   Veh         1.70              10.0

###### 

Genes regulated \> 1.5-fold by both conditional EP2 deletion and Aβ treatment.

  ------------------------------------------------------------------------------------------------------------------
  Gene symbol   Gene name                                                      Fold change\       Fold change\
                                                                               Aβ-EP2 vs. Aβ-WT   Aβ-WT vs. Veh-WT
  ------------- -------------------------------------------------------------- ------------------ ------------------
  Mir3094       MicroRNA 3094                                                  1.825              − 1.582

  Ly6c1         Lymphocyte antigen 6 complex, locus C1                         1.716              − 1.714

  Rabggtb       RAB geranylgeranyl transferase, b subunit                      1.638              − 1.844

  Serpinb1b     Serine (or cysteine) peptidase inhibitor, clade B, member 1b   1.514              − 1.687

  Pln           Phospholamban                                                  1.511              − 1.980

  Syne1         Syne1//synaptic nuclear envelope 1                             1.511              − 1.660

  Osm           Oncostatin M                                                   − 1.524            1.749

  Dusp1         Dual specificity phosphatase 1                                 − 1.542            1.824

  Dusp2         Dual specificity phosphatase 2                                 − 1.570            2.139

  Thap6         THAP domain containing 6                                       − 1.602            1.839

  Pmaip1        Phorbol-12-myristate-13-acetate-induced protein 1              − 1.660            2.036

  BC049715      cDNA sequence BC049715                                         − 1.715            1.594

  Gm20269       Predicted gene, 20269                                          − 1.873            1.848

  Il1r2         Interleukin 1 receptor, type II                                − 1.892            2.451

  Gm129         Predicted gene 129                                             − 1.899            1.880

  Fam71a        Family with sequence similarity 71, member A                   − 2.585            2.403
  ------------------------------------------------------------------------------------------------------------------

###### 

Genes regulated \> 1.5-fold by conditional EP2 deletion but not by Aβ treatment.

  --------------------------------------------------------------------------------------------------------------
  Gene symbol     Gene name                                                Fold change\       Fold change\
                                                                           Aβ-EP2 vs. Aβ-WT   Aβ-WT vs. Veh-WT
  --------------- -------------------------------------------------------- ------------------ ------------------
  Gpr114          G protein-coupled receptor 114                           2.413              1.453

  Lox             Lysyl oxidase                                            2.232              1.227

  Atp6v0d2        ATPase, H + transporting, lysosomal V0 subunit D2        1.924              1.166

  St8sia6         ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransfe   1.814              − 1.075

  Rdh13           Retinol dehydrogenase 13 (all-trans and 9-cis)           1.781              − 1.058

  Mamdc2          MAM domain containing 2                                  1.752              − 1.335

  Igf1            Insulin-like growth factor 1                             1.727              1.148

  Slc26a7         Solute carrier family 26, member 7                       1.701              − 1.344

  Gsdmc4          Gasdermin C4                                             1.689              1.055

  2210404O09Rik   RIKEN cDNA 2210404O09 gene                               1.684              − 1.087

  Tgtp2           T cell specific GTPase 2                                 1.681              1.103

  Pdcd1           Programmed cell death 1                                  1.652              1.015

  Cst7            cystatin F (leukocystatin)                               1.643              1.132

  Cd3g            CD3 antigen, gamma polypeptide                           1.617              1.025

  Rxrg            Retinoid X receptor gamma                                1.605              1.195

  Olfr1212        Olfactory receptor 1212                                  1.599              1.095

  Vmn1r184        Vomeronasal 1 receptor, 184                              1.570              − 1.114

  AF529169        cDNA sequence AF529169                                   1.553              1.088

  Olfr1052        Olfactory receptor 1052                                  1.549              1.011

  Olfr110         Olfactory receptor 110                                   1.549              − 1.291

  Olfr1313        Olfactory receptor 1313                                  1.540              1.009

  Axl             AXL receptor tyrosine kinase                             1.537              1.464

  Mir7-2          MicroRNA 7-2                                             1.524              − 1.187

  Gm4787          Predicted gene 4787                                      1.519              − 1.483

  Lpl             Lipoprotein lipase                                       1.516              1.055

  Gm4934          Predicted gene 4934                                      − 1.502            1.441

  Olfr221         Olfactory receptor 221                                   − 1.505            1.137

  BC031361        cDNA sequence BC031361                                   − 1.513            1.225

  Mir423          MicroRNA 423                                             − 1.524            1.080

  Gm10584         Predicted gene 10584                                     − 1.527            1.264

  A430078I02Rik   RIKEN cDNA A430078I02 gene                               − 1.532            1.380

  Hist3h2a        Histone cluster 3, H2a                                   − 1.584            1.291

  4933433G15Rik   RIKEN cDNA 4933433G15 gene                               − 1.623            1.343

  Mir3096b        MicroRNA 3096b                                           − 1.649            1.381

  G530011O06Rik   RIKEN cDNA G530011O06 gene                               − 1.671            − 1.081

  Hist4h4         Histone cluster 4, H4                                    − 1.698            1.513

  4833427F10Rik   RIKEN cDNA 4833427F10 gene                               − 1.780            1.492

  Ifnb1           Interferon beta 1, fibroblast                            − 1.876            1.443

  G530011O06Rik   RIKEN cDNA G530011O06 gene                               − 5.550            − 1.492
  --------------------------------------------------------------------------------------------------------------

[^1]: Equal contributions.
